TEL AVIV, Dec 11 (Reuters) - Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling...
TEL AVIV, Dec 11 (Reuters) - Teva Pharmaceutical Industries , the world's biggest generic drugmaker, forecast 2015 revenue below analysts' expectations and assumes its best-selling multiple sclerosis treatment will face competition in September.
(Adds information on earlier Teva settlement in paragraph 3)
Nov 26 (Reuters) - The board of Teva Pharmaceutical Industries Ltd elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost, who is due to step down at the end of the year.
have posted solid gains in this year's challenging conditions, including top-25 holdings Shire SHP, Teva Pharmaceutical Industries TEVA , Taiwan Semiconductor Manufacturing TSM, Baidu BIDU, and Avago Technologies AVGO. As a result, this
Although Teva ’s flat revenue growth during the third quarter ..... Despite weak growth trends in most of Teva ’s segments, the company’s cost reduction ..... performance over the coming quarters. Meanwhile, Teva ’s specialty drug segment posted stable
Mesoblast partner Teva Pharmaceuticals has announced it will discontinue ..... failure, or CHF, partnered with Mesoblast. Teva expects to realise cost savings of approximately ..... period which will be redirected towards Teva 's core therapeutic areas of central nervous
patient phase III trial in congestive hear failure partnered with TEVA is the most important of these being pursued with the MPC platform ..... valuation. Patient recruitment in the phase III trial partnered with TEVA is ongoing with interim results expected in 2015. Notably
PAGEBREAK> At the current time, the Appleseed Fund’s equity portfolio owns healthcare stocks such as Teva Pharmaceuticals ( TEVA ), Novartis (NVS), and PDI Inc. (PDII) due in part to our view that healthcare will continue to grow faster
outlook of $3.25 to $3.45 due to our estimate of an ongoing delay in key product launches, particularly a generic version of Teva ’s Copaxone. We have made no major changes to our longer-term forecast, including the integration of Abbott’s non